ORIGINAL ARTICLE
Year : 2022 | Volume
: 11 | Issue : 2 | Page : 91--97
AryoSeven RT (Coagulation factor VIIa, recombinant) safety and efficacy study among congenial factor VII deficient patients in Iraq
Nidal Karim Al-Rahal1, Ahmed Shemran Alwataify2, Safa Mohammed Shawkat3, Israa Almusawi4, Azeezah Mohammed Mohsin5
1 National Center of Hematology/Research & Management Unit for Inherited Bleeding Disorders/Mustansiriyah University, Baghdad, Iraq
2 Babylon Hereditary Blood Disease Center, Babylon Maternity & Children Hospital, Babylon, Iraq
3 Child Welfare Hospital - Medical City Teaching Hospital/Unit of Inherited Bleeding Disorders, Baghdad, Iraq
4 Karbala Hereditary Blood Disease Center, Karbala Teaching Hospital for Children, Karbala, Iraq
5 Basra Center for Hereditary Blood Disease , Basra Maternity & Children Hospital, Basrah, Babylon, Iraq
Correspondence Address:
Prof. Nidal Karim Al-Rahal
National Center of Hematology/Mustansiriyah University, Baghdad
Iraq
BACKGROUND: Recombinant activated factor VII (FVII) is a product onetime evolved to stop bleeding occurring in hemophilia A and B patients with inhibitor, congenital FVII deficiency, Glanzmann disease, and in life-threatening bleeding.
AIM: The aim was to evaluate the safety and efficacy of the coagulation factor VIIa, recombinant (AryoSeven RT) among congenital FVII deficiency patients at different centers in Iraq.
METHODOLOGY: This is a prospective, observational, noninterventional study done at 5 medical centers in Iraq and it included 22 patients with FVII deficiency (congenital form) older than 14 years of age. Patients are recorded and followed for 6 months and they are subjected to AryoSeven RT depending on each patient individually. There were 3 main visits and 3 unscheduled visits for each patient during the study. Effectiveness evaluation was performed 6 h after each intervention. Adverse drug reactions related to the administration of AryoSeven RT were reported for each patient during each visit.
RESULTS: A total of 22 participants were enrolled, classified into 18 (82%) were female and 4 (18%) were male. The mean age was 27.5 ± 14.0 years. Among 91 bleeding events, AryoSeven RT efficacy was effective in 89 events, excellent in 1 event, and partially effective in also 1 event. There was a reduction of PT from baseline (57.3 ± 15.2 s) to (13.9 ± 6.2 s) after 1st dose of AryoSeven RT and more reduction after 2nd dose of therapy (13.4 ± 4.4 s) and these were statistically significant (P = 0.001). Regarding FVII activity, there was a significant increase from baseline (8.4% ± 8.0%) to (95.8% ± 46.6%) after 1st dose and (131.8% ± 40.1%) after 2nd dose of AryoSeven RT with P = 0.001 for both. No major adverse events were reported except for headache in one participant (4.5%), and injection site reactions in three participants (13.6%).)
CONCLUSION: AryoSeven RT is safe and effective clinically and by laboratory data in stopping bleeding in patients older than 14 years with inherited FVII deficiency.
How to cite this article:
Al-Rahal NK, Alwataify AS, Shawkat SM, Almusawi I, Mohsin AM. AryoSeven RT (Coagulation factor VIIa, recombinant) safety and efficacy study among congenial factor VII deficient patients in Iraq.Iraqi J Hematol 2022;11:91-97
|
How to cite this URL:
Al-Rahal NK, Alwataify AS, Shawkat SM, Almusawi I, Mohsin AM. AryoSeven RT (Coagulation factor VIIa, recombinant) safety and efficacy study among congenial factor VII deficient patients in Iraq. Iraqi J Hematol [serial online] 2022 [cited 2023 Mar 22 ];11:91-97
Available from: https://www.ijhonline.org/article.asp?issn=2072-8069;year=2022;volume=11;issue=2;spage=91;epage=97;aulast=Al-Rahal;type=0 |
|
